RedHill Biopharma Wins Final $10.5 Million Judgment Against Kukbo
RedHill Biopharma Ltd. has won a final judgment of over $10.5 million against Kukbo Co. Ltd. from the New York Supreme Court. The award includes approximately $8.6 million in principal and around $1.9 million for legal fees. The principal judgment is final and enforceable, while the legal fees are subject to appeal until March 13, 2026. Both amounts will accrue 9% annual interest. Additionally, RedHill has secured a court order in Korea to prevent Kukbo from disposing of assets before the judgment is enforced.
RedHill Biopharma Ltd. has secured a final summary judgment in its favor from the New York Supreme Court in litigation against Kukbo Co. Ltd. The court awarded RedHill more than $10.5 million, consisting of a principal judgment of approximately $8.6 million and around $1.9 million for legal fees and expenses. The main judgment is now final and eligible for enforcement, while the award for legal fees and expenses remains subject to appeal until March 13, 2026. Both amounts will continue to accrue 9% annual statutory interest. Additionally, RedHill has obtained a court order in Korea to prevent Kukbo from disposing of assets ahead of enforcement of the judgment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO15033) on November 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
